Circulating tumour cells and tumour biomarkers in functional midgut neuroendocrine tumours
Open Access
- 23 January 2022
- journal article
- research article
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 34 (4) , e13096
Abstract
CALM‐NET was a phase IV exploratory study in the UK that aimed to evaluate if the presence of circulating tumour cells (CTCs) at baseline predicted symptomatic response in patients with midgut neuroendocrine tumours (NETs) treated with lanreotide autogel (LAN). Adults with functional, well/moderately differentiated (Ki‐67 0. Primary endpoint was the clinical value of baseline CTCs to predict symptomatic response (decrease in diarrhoea or flushing of ≥50% frequency, or ≥1 severity level). Other endpoints included progression‐free survival (PFS) and correlations between plasma and urinary biomarkers (including 5‐hydroxyindoleacetic acid [5‐HIAA]). Fifty patients were enrolled; 40 completed the study. Baseline CTCs were present in 22 (45.8%) patients (missing baseline CTC status n = 2). Overall, 87.5% (95% confidence interval [CI]: 73.9; 94.5) of patients had a symptomatic response; a 5.9‐fold higher odds of symptomatic response in patients without CTC versus patients with CTC at baseline was observed, although this was not statistically significant (odds ratio: 0.17 [95% CI: 0.02; 1.65], p = .126). One‐year PFS rate was 66.4% (95% CI: 48.8; 79.2). Biomarker concentrations did not correlate to baseline CTC status. However, there was a strong correlation between plasma and urinary 5‐HIAA (Spearman correlation coefficients ≥0.87 [p < .001], all time points). In conclusion, patients without CTC at baseline may be more likely to achieve a symptomatic response following LAN treatment than patients with CTC. Plasma 5‐HIAA correlated with urinary 5‐HIAA during LAN treatment. ClinicalTrials.gov identifier: NCT02075606.Keywords
Funding Information
- Ipsen
This publication has 29 references indexed in Scilit:
- Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II studyBMC Cancer, 2013
- Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2011
- Circulating Tumor Cells and EpCAM Expression in Neuroendocrine TumorsClinical Cancer Research, 2011
- Circulating tumour cells: their utility in cancer management and predicting outcomesTherapeutic Advances in Medical Oncology, 2010
- Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing ChemotherapyThe American Journal of Pathology, 2009
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate CancerClinical Cancer Research, 2008
- Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004
- Rapid and Sustained Relief from the Symptoms of Carcinoid Syndrome: Results from an Open 6-Month Study of the 28-Day Prolonged-Release Formulation of LanreotideNeuroendocrinology, 2004
- Prospective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumors—The International Lanreotide and Interferon Alfa Study GroupJournal of Clinical Oncology, 2003